title: Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
abstract: 61 patients with small cell lung cancer in a poor prognosis group were treated with chemotherapy and with thoracic radiotherapy if they had 'limited stage' disease. No prophylactic cranial irradiation was given. Chemotherapy comprised doxorubicin 50 mg/m2 and ifosfamide 5 g/m2 with mesna on day 1, and etoposide 120 mg/m2 intravenously on days 1 and 2 and 240 mg/m2 orally on day 3. Treatment was repeated every 3 weeks for a maximum of six courses and no dosage reductions were allowed. Complete response rate in limited stage patients was 55% and 16% in extensive stage patients. The partial responses were 38% and 66% respectively. Overall median survival was 10.5 months with 2-year survival of 14%. The corresponding values for limited stage disease were 13 months and 16% and for extensive stage disease 8 months and 13%. Despite the addition of doxorubicin at a somewhat higher dosage than usual in this type of regimen and a policy of no dose reduction, toxicity was generally mild. There was, however, a 19% relapse rate in complete responders in the brain, apparently as the sole site of disease.
authors.affiliation: Department of Medical Oncology, Christie Hospital, Manchester, U.K.
authors.forename: A G
authors.initials: AG
authors.lastname: Kamthan
authors.forename: M J
authors.initials: MJ
authors.lastname: Lind
authors.forename: N
authors.initials: N
authors.lastname: Thatcher
authors.forename: W P
authors.initials: WP
authors.lastname: Steward
authors.forename: M H
authors.initials: MH
authors.lastname: Bronchud
authors.forename: M R
authors.initials: MR
authors.lastname: Ranson
authors.forename: R
authors.initials: R
authors.lastname: Stout
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D007069:Ifosfamide